MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

Evalytics 31 October at 05.22 PM

Alzheimer’s drug Leqembi could be given as shots rather than IV infusion, study suggests


Leqembi's New Administration Method: The Alzheimer’s drug Leqembi, the first to slow the disease's progression, may soon transition from bi-weekly intravenous infusions to two weekly shots administered at home, as suggested by a study from drugmaker Eisai. This alternative method aims to provide a more convenient treatment process for patients.

Study Findings and FDA Approval: Research presented at the Clinical Trials on Alzheimer’s Disease conference in Boston indicated that the shot version, given subcutaneously, produced results similar to the IV method over a span of six months. These results encompassed safety metrics, drug concentration in the bloodstream, and the ability to clear amyloid plaques in the brain.

Future Prospects and Considerations: Eisai is gearing up to file an application for FDA approval of the weekly shot form by the end of March next year. The shots could be self-administered or given by a caregiver. However, it's crucial for prescribers to ensure patients are well-informed on its use and can consistently administer it, alongside appropriate safety monitoring.

Read Full Article

Recent Comments


  • avatar